Highlights

  • Pro Medicus Limited (ASX:PME) has published 2026 company and financial updates.
  • Reported revenue: AUD 261.7 million.
  • Reported earnings: underlying EBIT of AUD 196.1 million and underlying net profit after tax of AUD 144.7 million.
  • The company declared a fully franked final dividend of AUD 0.37 per share.

Pro Medicus Limited, listed as (ASX:PME), operates in medical imaging software and clinical workflow technology. The business has reported developments during 2026 concerning its operations, financial position and near-term priorities. On 21 October 2026, Pro Medicus Limited (ASX:PME) was quoted at AUD 184.39, with a daily change of +2.48% for the trading session. Its recent disclosures provide a basis for assessing reported activity without attributing the daily price movement to any particular announcement.

Company Business

The core operations of Pro Medicus Limited (ASX:PME) span serving hospitals and imaging providers particularly in North America, as well as other international markets. Its Visage imaging platform supports viewing, workflow and archive functions; the company has also introduced digital pathology and AI-optimised reporting products. This portfolio exposes the company to procurement decisions, healthcare budgets and clinical or consumer demand in its operating markets. The reported financial performance depends not only on sales volumes, but also on product mix, service delivery requirements and operating expenses. The company's activities should therefore be considered through both its operating disclosures and its detailed financial reporting.

Recent Development

In August 2026 the company reported 10 new contracts with a combined minimum value of AUD 407 million and six contract renewals worth AUD 141 million over five years. Pro Medicus Limited (ASX:PME) has continued to report business activity through official investor communications. The company declared a fully franked final dividend of AUD 0.37 per share. Such developments are distinct from the daily market quotation and should be considered against the timing and scope described in each company release. Operational initiatives also require ongoing execution, and announced projects should not be treated as completed until the relevant company confirms delivery.

Financial Performance and Sector Context

For its latest published 2026 reporting period, Pro Medicus Limited (ASX:PME) disclosed revenue of AUD 261.7 million. It also reported underlying EBIT of AUD 196.1 million and underlying net profit after tax of AUD 144.7 million. Additional financial information included cash and other financial assets of AUD 252.3 million, with no debt reported. Statutory net profit after tax was AUD 265.3 million, while the underlying EBIT margin was 74.9%. The distinction between statutory and underlying earnings is material. These figures reflect the company's own reporting definitions, and adjustments labelled underlying or normalised should not be confused with statutory results. Healthcare demand can differ across products and geographies, while reimbursement decisions and currency changes may affect reported outcomes. Monitoring the relationship between sales, operating expenditure and cash conversion remains important when comparing reporting periods.

Risks to Consider

Business and industry risks for Pro Medicus Limited (ASX:PME) include Contract implementation schedules, dependence on institutional customer procurement, software integration, international sales concentration and currency conversion. Commercial contracts and clinical products can be affected by regulatory approvals, purchasing cycles or changes in provider capacity. Even where sales are recurring, cost inflation and implementation spending can alter profitability. Overseas operations may also introduce foreign exchange translation differences. The materiality of each risk will depend on the company's latest operational experience and the financial information it releases. Risks should be distinguished from confirmed adverse outcomes; an exposure does not establish that a loss will occur.

What to Watch Next

Future disclosures from Pro Medicus Limited (ASX:PME) may clarify Implementation of new healthcare contracts, progress on the Trinity deployment, software product rollout and recurring revenue recognition. The next results statement may also indicate whether announced initiatives are reflected in operating margins, cash flow or capital expenditure. Readers can compare management's stated plans with completed activities and monitor how changes in service demand, procurement and pricing appear in official releases. Dates for meetings, reporting and other milestones should be checked against any later corporate announcements rather than assumed to remain unchanged.

Key Insights

Pro Medicus Limited (ASX:PME) combines its established operating activities with developments reported during 2026. Its most recent official results and statements provide information about earnings, business priorities and identifiable operating risks. The market quotation for 21 October is a separate trading observation and does not establish a cause for price movement. Subsequent company disclosures will be relevant for assessing progress on operational initiatives, financial performance and the use of capital. Any interpretation should preserve the distinction between reported results, management targets and outcomes that have not yet occurred.